Robert Casella
AstraZeneca (United States)(US)
Publications by Year
Research Areas
Crystallization and Solubility Studies, Drug Solubulity and Delivery Systems, Analytical Methods in Pharmaceuticals, T-cell and B-cell Immunology, Synthesis and biological activity
Most-Cited Works
- → Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies(2020)100 cited
- → The physicochemical characteristics and bioavailability of indomethacin from β-cyclodextrin, hydroxyethyl-β-cyclodextrin, and hydroxypropyl-β-cyclodextrin complexes(2003)89 cited
- → Pyrimidinone Nicotinamide Mimetics as Selective Tankyrase and Wnt Pathway Inhibitors Suitable for in Vivo Pharmacology(2015)65 cited
- → Solid-state β-cyclodextrin complexes containing indomethacin, ammonia and water. I. Formation studies(1998)36 cited
- → Solid-state β-cyclodextrin complexes containing indomethacin, ammonia and water. II. Solubility studies(1998)24 cited
- → Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 Inhibitor(2025)16 cited
- → Quantitative measurement of crystalline impurity in a pharmaceutical tablet by X-ray powder diffraction and method validation(2013)1 cited
- → Synthetic chemistry enabling the discovery and development of a series of pyrazoles as HPK1 inhibitors(2025)1 cited
- → Direct Compression Tablets Containing a Series of Four β-Cyclodextrin Complexes Formed by Neutralizing an Acidic Drug(2000)1 cited
- → 889: Predictive Accuracy, Sensitivity, and Specificity of Nuclear Matrix Protein 22 and Urine Cytology for Prediction of Recurrence of Non-Transitional Cell Carcinoma of the Bladder(2006)